Speaker illustration

Doctor Florian Alexander Wenzl

University of Zurich, Zurich (Switzerland)

Member of:

European Society of Cardiology

Florian Wenzl completed his medical degree with highest honours at the Medical University of Graz, Austria. Subsequently, he trained at the Heart and Vascular Center, University of Pennsylvania and continued his cardiology fellowship at the German Heart Centre Munich. Since 2021, he pursues his PhD at the University of Zurich/Swiss Federal Institute of Technology (ETH) Zurich. He received multiple research and educational grants from public and private sources. Florian and his team aim at enhancing risk prediction in cardiovascular disease. As a fellow of the SPUM-ACS, AMIS Plus, and MINAP studies, he focuses on large-scale investigations and conducted research stays at the University College London and the Cardiovascular Research Institute Basel. For his efforts in research and education, he received numerous prizes and awards, including the Ars Docendi national prize awarded by the Austrian Minister of Education. In his free time, he plays Tennis and enjoys cycling with friends.

Sex inequities in the performance of the GRACE 2.0 score in non-ST-segment elevation acute coronary syndromes: a multinational observational study in contemporary cohorts from four European countries

Event: ESC Congress 2022

Topic: Non-ST-Elevation Myocardial Infarction (NSTEMI)

Session: What defines risk in acute coronary syndromes

Thumbnail

Bleeding risk in patients hospitalized for non-ST-segment elevation acute coronary syndromes in Switzerland: performance of the CRUSADE score

Event: ESC Congress 2022

Topic: Non-ST-Elevation Myocardial Infarction (NSTEMI)

Session: What defines risk in acute coronary syndromes

Thumbnail

Remnant cholesterol contributes to residual lipid risk after acute coronary syndromes

Event: ESC Congress 2022

Topic: Epidemiology, Prognosis, Outcome

Session: Coronary artery disease - Epidemiology, prognosis, outcome 5

Thumbnail

This platform is supported by

logo Novo Nordisk